Cambridge Clinical Laboratories to offer prostate cancer gene test Prostatype to UK healthcare facilities
Cambridge Clinical Laboratories (CCL) has struck a deal with Prostatype Genomics to bring its prostate cancer gene test to the UK market.
Milton-based CCL will offer the Prostatype test in its own lab and promote the test to uro-oncological facilities across the UK and Ireland.
Dr Anthony Cooke, CEO of CCL, said: “The Prostatype test, identifying the genetic fingerprint of cancer, is exactly the kind of smart and innovative solution we want to introduce, implement and drive.”
Prostatype measures information from cancer stem cell genes. The gene expressions, together with other clinical parameters such as PSA levels, Gleason score and tumour stage are entered into the Classification of Prostatic Malignancy Algorithm (CPMA) software, linked to a unique patient database.
The software calculates the so-called P-score that provides a measure of how aggressive the cancer is, which guides treatment choice for patients.
Prostatype Genomics CEO Fredrik Persson said: “We are very happy to be working together with Cambridge Clinical Laboratories, they have an impressive reputation for constantly pushing the envelope when it comes to finding new technologies and smart solutions that create value for healthcare and help patients. Stepping into these new and exciting markets, this agreement will be key.”
CCL, which began life as Lab 21 in 2005, aims to be an early adopter of new technologies for diagnostics and help the drive towards personalised medicine.
More than 99,000 tests have been carried out and more than 400 customers supported since the company launched.
CCL, which also offers Covid-19 testing services, became UKAS accredited to the ISO15189 standard for medical laboratories in 2018.